Cost-effectiveness of treating schizophrenia with atypical antipsychotics

被引：0
|
作者：
Lewis, M [1 ]
Frangou, S [1 ]
机构：
[1] Inst Psychiat, Sect Neurobiol Psychosis, London, England
来源：
SCHIZOPHRENIA RESEARCH | 2003年 / 60卷 / 01期
关键词：
D O I：
10.1016/S0920-9964(03)80332-8
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：338 / 339
页数：2
相关论文
共 50 条
  • [21] VALIDATING AN INDUSTRY-SPONSORED MODEL COMPARING THE COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA
    Graham, Christopher N.
    Mauskopf, Josephine
    Lawson, Anthony H.
    Ascher-Svanum, Haya
    Bruhn, David
    Watson, Peter R.
    SCHIZOPHRENIA RESEARCH, 2010, 117 (2-3) : 398 - 399
  • [22] A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda
    Lubinga, Solomon J.
    Mutamba, Byamah B.
    Nganizi, Angelo
    Babigumira, Joseph B.
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2015, 13 (05) : 493 - 506
  • [23] Cost-effectiveness of atypical antipsychotics for treatment of acute mania in the UK
    McGarry, L
    Bird, AP
    Thompson, D
    Cookson, J
    Martin, SC
    Weinstein, MC
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S261 - S261
  • [24] Cost-effectiveness of atypical Antipsychotics in the CATIE Alzheimers disease trial
    Rosenheck, RA
    NEUROPSYCHOPHARMACOLOGY, 2005, 30 : S42 - S43
  • [25] Cost-Effectiveness Model Comparing Olanzapine and Other Oral Atypical Antipsychotics in the Treatment of Schizophrenia in the United States
    Svanum, Ascher H.
    Furiak, N. M.
    Klein, R. W.
    Smolen, L. J.
    Lawson, A. H.
    Conley, R. R.
    JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2009, 12 : S3 - S4
  • [26] Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States
    Furiak N.M.
    Ascher-Svanum H.
    Klein R.W.
    Smolen L.J.
    Lawson A.H.
    Conley R.R.
    Culler S.D.
    Cost Effectiveness and Resource Allocation, 7 (1)
  • [27] Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia
    Park, Taehwan
    Kuntz, Karen M.
    VALUE IN HEALTH, 2014, 17 (04) : 310 - 319
  • [28] Cost-effectiveness simulation analysis of schizophrenia at the Instituto Mexicano del Seguro Social: Assessment of typical and atypical antipsychotics
    Mould-Quevedo, Joaquin
    Contreras-Hernandez, Iris
    Verduzco, Wascar
    Manuel Mejia-Arangure, Juan
    Garduno-Espinosa, Juan
    REVISTA DE PSIQUIATRIA Y SALUD MENTAL, 2009, 2 (03): : 108 - 118
  • [29] Can typical and atypical antipsychotics show differential effectiveness in treating paranoia and hallucinations in schizophrenia?
    Osimo, Emanuele F.
    Goujon, Marie Juliette
    Perez, Jesus
    Murray, Graham K.
    BMJ CASE REPORTS, 2019, 12 (03)
  • [30] Cost-Effectiveness of Treating Schizophrenia with Ziprasidone versus Other Antipsychotics Considering Adverse Drug Reactions and Non-Compliance
    Volz, H. -P.
    Sadre-Chirazi-Stark, M.
    Resch, A.
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2005, 10 : 96 - 101
12345